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AIDS was  first identified in the United States way back in 1981predominantly 
in people having monogamous relationship, and Human Immunodefiency Virus was 
later detected as the causative organism. While starting it is  limited, infection with 
the human immunodeficiency virus increased rapidly over the last half a century to 
become the most deadliest epidemic in the whole world. According to December 
2009, 33.1 million people were approximated to be infected and living  with 
HIV/AIDS, and more than 35.1 million had died from the beginning in the epidemic 1. 
Asia is the rapidly increasing in the HIV infected people and majority found in the 
sub- Saharan africa. Profound immunodeficiency is found in HIV infected individual 
is hallmark of HIV due to progressive decline in  helper T cells.  
 CD4 cells decline in number below a certain level is high risk for various 
opportunistic diseases to develop in particularly neoplasia and infection that in AIDS 
– defining illnesses. Detection of Human Immunodeficiency Virus  by tracing its 
antibodies  and also  direct detection of Human Immunodeficiency Virus  or its 
components helps for the diagnosis of HIV infection. ELISA is used for screening test 
for HIV infection and confirmatory by WESTERN BLOT. The best indicator for 
patients with HIV infected is identified as CD4 + T cells level in laboratory test and to 
know immunologic competence in same patient. Human immunodeficiency virus 
found to be etiology for broad spectrum  of infectious,neoplastic and immunologic 
complications. Followed diseases are major concern in HIV course and anemic are 
also observed may complicate the all condition in HIV patients.  
Anemia is rarely a fatal complication, however it does significantly increase 
the morbidity as well as precepitates preexisting illnesses. Hence these patients found 
to be reduced survival in high risk Human Immunodeficiency Virus patients. The 
prevalence of anemia in patients with Human Immunodeficiency Virus  varies 
between 10% in asymptomatic patients  to 92% in persons with full blown AIDS2. In 
Human Immunodeficiency Virus  patients, anemia is a predictive feature of  disease 
progression or death, independent of CD4 and viral load2. Anemia impacts a range of 
dimensions of quality of life. The common causes of anemia in HIV and non HIV 
patients are varied so treatment will differ. By knowing knowledge of  the association 
of anemia and HIV infection is important it helps in treatments for anemia are 
available including  r-human erythropoietin, blood transfusion, and in drug causing  
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anemia, terminating of myelosuppressive therapies. Hence knowledge of the 
pathophysiological mechanisms and the prevalence of various causes of anemia will 
help us in treatment of anemia in HIV positive patients. Very few studies have 
examined factors associated with anemia in the setting of a developing country. 
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2. AIMS AND 
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
1. To study the etiology of anemia in HIV positive individuals admitted in 
medical ward. 
2. To study the relationship between anemia and immunological status as 
indicated by the CD4 counts  
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3. REVIEW OF 
LITERATURE 
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      AIDS was  first identified in the United States way back in 1981predominantly in 
people having monogamous relationship, and Human Immunodefiency Virus was 
later detected as the causative organism3, 4. Around months the disease became clear 
in male and female individuals, intravenous  injection drug addicts and also found in 
recipients of blood transfusions and hemophiliacs. In 1983 Luc Montagnier isolated 
HIV from AIDS patient found with lymphadenopathy 5. In 1985 a precise assay well 
discovered leading to the early diagnosis and new era of the HIV pandemic 
worldwide 6. In the initial days people living with HIV/AIDS (PLHA) had little hope. 
The introduction of antiretrovirals was a turning point for hundreds of thousands of 
people. HIV patients have expanded over the past few to become the dangerous 
epidemic of the last century.  
 
 
EPIDEMIOLOGY  
Incidence and prevalence worldwide 7.  
AIDS is a global  pandemic with more  cases reported from virtually every 
country. As per the 2015 WHO update the no.of people living with AIDS was around 
36 million. This includes 18 million women. 
Individuals with AIDS in the year 2015 was around 2.1 (1.8-2.4) million. It 
was nearly 28% less than the 2.6 million people newly infected in 2009, and greater 
than 30% less than the estimated 3.million [2.9 million–3.4 million] in 1999, where 
new infections peaked. The total numbers of AIDS deaths in 2015 were 1.1 (0.94 -
2.1) million. The HIV epidemic happened in waves in various parts of the world, each 
wave having different features depending on the region’s demographics, region in 
question and timing for introduction of HIV into the common population. The various 
subtypes of HIV-1 are common in various regions of the world, increasing the more 
difficult in discovery of vaccines and indicate the various degrees of virulence. 
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FIGURE 1: PREVALENCE OF HIV INFECTED PEOPLE 
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FIGURE 2: INCIDENCE OF ADULT +  CHILD DEATHS WITH HIV 
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FIGURE 3: INCIDENCE OF ADULTS + CHILDREN WITH  NEWLY 
INFECTED  HIV 
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Indian scenario 8 9  
            Of the 5.1 million HIV-infected persons found  infected  in Asia, mostly 
people in living in India. India had an estimated 2.1( 1.71 – 2.64) million HIV 
infected persons in 2015, with an measured adult HIV prevalence of 0.26% (0.22%–
0.32%). There is a decreasing trend of people living with AIDS in the country, from 
2.6 million in 2009 to 2.2 million in 2015. Women  
account for 40.5percent of PLHA while children account for 6.54%. Subtype C of M 
group of  HIV -1 is the mostly found prevalent worldwide and in India 10  
 
 
FIGURE 4: PREVALENCE OF NEW HIV INFECTED PEOPLE  IN INDIA 
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CLINICAL MANIFESTATIONS 
 
FIGURE 5: NUMBER OF PEOPLE WITH HIV INFECTED ON ART 
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FIGURE 6: DISTRIBUTION WITH  PLHIV IN DIFFERENT STATES IN 
INDIA 
 
 
 
 
FIGURE 7: DISTRIBUTION WITH  PLHIV IN DIFFERENT STATES IN 
INDIA 
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Acute HIV Syndrome  
Acute HIV syndrome occurs 3-6 weeks after infection in 50-70% of infected 
individuals and can vary in severity from individual to individual. It presents as an 
acute  mononucleosis like illness. Symptoms last one to several weeks  
 
Asymptomatic Stage/Period of Clinical latency  
            The progression to clinical disease occurs in about10 years. Patients are 
usually asymptomatic during this period or may continue to have persistent 
generalized lymphadenopathy. Dermatological manifestations may occur.  
 
Symptomatic/Intermediate Stage  
   This is the stage when the CD4 count is between 200/μl to 500/μl. Usual  
complications at this stage include dermatological, oral and constitutional 
manifestations.  
 
Stage of AIDS  
 
  The CD4+  count is lower than 200permicrolitre in these patients. The  
opportunistic infections, neoplasms and neurological disorders seen at this stage 
constitute the AIDS defining conditions  
 
 
Centre for Disease Control classification system for patients with HIV infection 
in adults and adolescents 10  
 
   The latest Centre for Disease Control classification in  patients with HIV 
infection in adults and adolescents classifies persons with the underlying of clinical 
conditions along with HIV infected and CD4+ T lymphocyte counts. The 
classification differentiates three ranges of CD4+ T lymphocyte 11 
 
Counts and there are three clinical categories also represent with nine mutually 
exclusive categories 
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Table -1 
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WHO staging system for HIV infection in adults and adolescents 11
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Hematologic manifestations in HIV infection  
              Anemia,leukopenia,lymphadenopathy, and thrombocytopenia are common 
disorders in hematapoietic system throughout all course of HIV infected individual 
and found it was a result of AIDS, shows features of 20 malignancies and infections 
and some adverse effects of treatment. Most of patients, or else asymptomatic, also 
develop persistent whole lymphadenopathy of early clinical manifestation in HIV 
infected person. This conditions are verified by the presence of lymphadenopathy in 
greater extrainguinal sites for more greater than 2 months without an clearly seen 
etioligy. The enlarged lymph nodes is because of the prominent follicular enlargement 
in  infected node due to AIDS. Infected cases with CD4+ T cell counts  greater than 
200per microliter, the observed diagnosis of lymphadenopathy also consists  of 
Kaposi sarcoma, Tb, Castleman's disease, and lymphoma. Infected cases with 
advanced infection, lymphadenopathy can be found due to atypical mycobacteria, 
systemic fungi, and or bacillary  angiomatosis.  
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TREATMENT12 
Initiation of ART by level on CD4 count and developed by WHO clinical staging:  
CD4 count available      
                – Stage IV: Irrespective of CD4 count  
               – Stage III: CD4 count < 350/μl  
               – Stage II & I: CD4 count < 200/μl  
 
CD4 count not available  
 
                 – Stage IV & III: Treat  
                – Stage II & I : Do not treat  
 
 
Recommended choice of first line regimens:  
Choose lamivudine in all regimens; Choose one NRTI to combine  with lamivudine; 
Choose one NNRTI  
Preferred first line regimen : AZT + 3TC +NVP  
Alternate 1st  line regimens :  
 
                      AZT + 3TC + EFV  
 
                      D4T+ 3TC + (NVP or EFV) 
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ANEMIA  
            Anemia is identified by a decline in Hb or Hct  value in an persons  normal 
value. Because of person normal Hb  levels mostly are not well appreciated, specific 
for sex and race  determine the  reference ranges are always used for the working 
diagnosis in anemia. In general population, normal  Hb  values are 1 to 2 g/dL lower 
in female  and also in African American male and  than in white male. WHO criteria 
used for anemia to diagnose in men and women are <13 & <12 g/dL, respectively 13. 
These criteria are meant and to be used around within the context of international 
nutritional  studies, and are not initially designed to used as gold standards to the 
diagnosis of anemia.  
 
Normal ranges used for population with in a higher incidence of chronic 
disease may also be skewed following anemic levels. Thus, anemia is very difficult to 
diagnosis in countries in which malnutrition,added infection (example : HIV 
infection/ tuberculosis) and/or congenital related  hematologic disorders are  common.  
 
Clinical consequences  
            Grades of anemia is used for to asses signs/symptoms of anemia related and  
also the rate at which it has evolved, along with the oxygen demands of infected   
patient. Symptoms are observed as much less with anemia that shows slowly, because 
there is time for various factors influence to multiple homeostatic  forces to make 
adjust for  reduced oxygen carrying capacity of blood.  
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CLASSIFICATIONS OF ANEMIA  
Physiologic classification 
 
      Disorders resulting in an inability to adequately produce red blood cells . 
Disorders resulting in rapid RBC destruction (hemolysis) or RBC losses from the 
body  
 
 Etiology of the anemia is very well evaluated with the reticulocyte count. 
With  increased reticulocyte count mostly  is seen as  normal bone marrow response 
for ongoing  hemolysis / non continuous blood loss. On the other side,  low 
reticulocyte count, which shows decreased production of erythrocytic cells,and is 
more consistent to show  with bone marrow depression.  
 
These two categories are not mutually exclusive.  
 
 
Morphologic classification  
o Normocytic  
o Microcytic  
o Macrocytic 
 
 (WHO)/AIDS Clinical trial group (ACTG) criteria of anemia grades  for both men 
and women are as follows 29:  
 
o Grade one 9.5–10.9 g/dl  
o Grade two 8–9.4 g/dl  
o Grade three 6.5–7.9 g/dL  
o Grade four < 6.5 g/dL  
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The following figure shows the physiologic classification of anemia 
 
FIGURE 8: PHYSIOLOGIC CLASSIFICATION OF ANEMIA10 
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ANEMIA IN HIV INFECTION  
 
    Anemia  in HIV infected patients with incidence reflect varies  from 10 - 12% is 
with no symptomatic patients up to 90 - 93%  persons with fully infected AIDS 2. 
Most  common hematologic variation is seen is anemia associated with HIV infected 
15. Eventhough  it cause very  rarely a death leading problems  of HIV disease but 
anemia may moderately increase death rate  in HIV infected patients.16 17 The 
presence of anemia is always  related  to  increased morbidity and mortality in both 
children and adults with HIV infection 18 -  
 
           Anemia had risk factors to developed were evaluated in a brief manner from 
the HIV Study (WIHS) &  four mojor  factors are  identified: Mean corpuscular 
volume (MCV) <80 fL,  HIV-1 viral load ≥50,000/mL,CD4 count <200/microL and 
use of AZT  in past six months16. Inspite of development of HAART, HIV-caused 
anemia is more common, and independently accompany risk for decreased survival 21 
22  
 
Possible role of HIV  
 
     HIV as single factor leads to be a major contributor to show variables in 
hematopoeisis. HIV infected has been very clearly demonstrated in CD4+ 
lymphocytes, monocytes, macrophages, and dendritic cells 23. In comparison, diseases 
of CD34+ bone marrow progenitor cells remains controversial. The in vitro ability of 
HIV to infect CD34+ cells from  healthy donors has been suggested by finding viral 
inclusions on electron microscopy 24 and demonstrated by nucleic acid amplification 
25 . However, most investigators have been unable to  detect 26 or have detected only 
small amounts of HIV-derived DNA 27 from CD34+ progenitor  cells isolated from 
HIV-positive patients. Furthermore, the most primitive subset of CD34+ cells appear 
to be increased in resistant to HIV people, despite HIV receptor expression. 
 
According to kreuzer et al29 potential pathogenetic etiology of anemia in HIV 
positive patients are HIV infection of hematopoietic stem cells or red cell  progenitor  
Bone marrow diseases like  (Mycobacterium tuberculosis and  atypical variant)   Bone 
marrow malignancies  like  (NHL, HL  and Kaposi’s  sarcoma)  
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o Myelosuppressive drugs like  (Zidovudine , Ganciclovir)  
o Vitamin B12, serum folate level, iron related deficiency  
(undernourised and under absorption, disturbed usage)  
o Autoimmune RBC  hemolysis like  (erythrocyte cell auto antibodies, 
and flowing immune complexes)  
o Loss of Blood  due to (Internal bleeding)  
 
 
PERIPHERAL BLOOD AND BONE MARROW  
  
               Most common variant of anemia is mostly  normocytic normochromic. 
Erythrocyte cell morphology is more time observed  as normal but abnormalities such 
as poikilocytosis,rouleaux formation and other formations have been reported30. 
Factors unrelated to HIV infection also cause  microcytosis and macrocytosis. 
Macrocytic anemia is closely observed and reported very frequently in patients on 
HAART. Most favour cause of macrocytic anemia in HIV infected  patients is 2o to 
HAART29. In bone marrow a different types of morphologic characteristics have  
been described, ranging from normal hematopoeisis to bone marrow dysplasia, 
plasmacytosis, reticulin fibrosis,  lymphocytic infiltration, granulomatous myelitis, 
and other conditions32. The mechanism of HIV related to induced bone marrow 
changes and peripheral blood changes are observed as a  either directly related effect 
of HIV, nutritional related deficiencies,secondary related frequent  opportunistic 
infections or bone marrow  related suppression by drugs and other involved factors. In 
one study done by  Tripathi et al in Lucknow,India, bone marrow examination was 
normocellular in 76%, hypocellular in 7% and hypercellular in 16% patients32. In 
another study done by Xiaohui  in 32% had hypocellular, 32% had hypercellular 
marrow, 35% had hypercellular marrow 33. Bone marrow varities are seen in mostly 
of all stages of  disease, and increasing in the thing as the disease  going on. Infection 
like marrow mesenchymal stem cells also been observed as the main factor causing 
bone marrow defects and all34. Intense vacuolization specially  in the granulocyte 
element is frequent. Irregularerythropoiesis  may also  manifest as more megaloblastic 
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change. This changes was found not related to serum cobalamin and serum folate 
levels or to other drug therapy with zidovudine related or folate  antagonists related, 
although these all drugs also may accentuate it 35. According to Pardela et al36 90%of  
patients of patients are  very strongly  showed  to be  have bone marrow irregularity 
during the full course of  disease  
 
 
ETIOLOGY OF ANEMIA  
ANEMIA OF CHRONIC DISEASE  
    Anemia due to  chronic disease is found as the most related  favour cause of 
anemia in HIV-infected patients. Anemia due to chronic disease is explained as 
anemia  mostly not able to be explained by detailed  mechanisms and is special thing 
as by low level of ferremia in the picture of  With enough  fe stores with normal or 
high ferritin. Red cells are mostly commonly seen as normocytic and normochromic; 
there may be with  mild or moderate anisocytosis with a few microcytes37.  
 
Most  of the mechanisms are   
               Direct correlate toxic effect of human immune deficiency virus  infection  on 
hematopoietic stem cells / bone marrow   
             Irregular  habit of inhibitory cytokines.  
             Decrease level  of erythropoietin  
            Defective mechanism in  iron metabolism & reused.  
 
         HIV may have direct toxic effect on the bone marrow. According to Means et al 
bone marrow stromal cells also mostly be infected with HIV38. Eythroid precursors 
(glycophorin A positive) can  also express CD4 antigen related  and thus can be 
infected with Human immunodeficiency virus39 . There is directly related cytotoxic 
effect of HIV seen on various hematopoietic stem cells and  as well also on stromal 
environments of the bone marrow. This results to decline in  production of IL-3 and 
G-CSF leads to defective erythropoiesis 40.  
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                    Abnormal expression of the cytokines it affects the most of  bone 
marrow. The bone marrow and its micro environment has a major role in 
hematopoeisis and is affected by both cellular and humoral factors. All like T cell 
receptor (gamma delta T cell receptor positive lymphocytes)   cytokine induced 
signaling   also decline  progenitor growth in vitro 41. Interferon gamma  has also 
shown to stop growth action of CFU-E through straight receptor binding 42. 
Transforming growth factor beta can also  suppress progenitor growth in vitro43. 
Study by Fuchs et al has shown that inhibitory effect TNF-alpha, IL-1, and IFN-
gamma on bone marrow erythropoiesis contributes to marrow hypoplasia. 
  
Decreased erythropoietin production and decreased responsiveness of stem 
cells to erythropoietin has been postulated as a mechanism of anemia in HIV positive 
patients 44. All patients  compared  with routine  iron deficiency anemia,found to be  
inadequately less level of erythropoietin  again and again reported in HIV infected  
patients 45 46. In treatment as additional with r-erythropoietin had a particular  
significant  effect in  large  number of  anemic human immunodeficiency virus 
individuals 47 48 . This made to the hypothesis that says  HIV induced anemia may be 
at  less likely  due to reported  hypoerythropoeitinemia. Pro inflammatory cytokines, 
TNF alpha & IL-1 beta may  happen  to less renal erythropoietin synthesis.  
  
 Inflammation induced anemia is hall mark to the development of disturbances 
in normal Fe homeostasis, with incline in  retention and uptake  of Fe around cells of 
RE system. The immune effector mechanisms produce cytokines like TNF alpha, IL-
1, interferon gamma, ,IL-6 and IL-10. This stimulates the hepatic activity in acute 
phase protein hepcidin , this expression  stops  duodenal uptake of Fe. Interferon 
gamma it increases the action of divalent metal transporter-1 on macrophages & 
stimulates the absorption of Fe+ iron. It also may  decrease the action of macrophage 
iron transporter  Ferroportin-1, and stop iron take up in macrophages,and a way  that 
is involved and involved  by hepcidin 49. Ferritin  concentrations incline with Human 
immunodeficiency virus disease process, and Fe settles  in most  tissues. Fe  excess 
may also shows  negative effects because of an  Fe-mediated  oxidative stress in 
patients  with Humanimmunodeficiencyvirus  infection. Iron-mediated oxidative 
stress may contribute to viral cytopathogenicity and iron storage seems to be 
associated with shorter survival29.  
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The various factors involved in anemia of chronic disease are depicted below:  
 
FIGURE 9: FACTORS IN ANEMIA OF CHRONIC DISEASE 
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HIV-RELATED INFECTIONS  
Bone marrow in HIV patients  are the most likely bacterial pathogen to infect 
with atypical mycobacteria. Erythroid hypoplasia was happen  to be a distinctive 
feature associated with  mycobacterun avium intracellulare (MAI) infection. In the 
study by Gardener et al says  bone marrow provided a high yield for microbiological 
culture, particularly in MAI infection 50 . In the  study by Fuller et al says most 
infectious leads of anemia in HIV- patients due to bone marrow infection include  
tuberculosis, histoplasmosis, parvovirus B19 , cryptococcosis, and pneumocystis 
jirovecii and toxoplasma gondii apart from MAI 51. Opportunistic infections in the 
gastrointestinal tract including microsporidia are most  likely to involved in 
mechanism of anemia by major  cause  to Fe, vitamin B12 and related folate 
underabsorption 52. In a prospective study by David et al done in 106 adults admitted 
consecutively to medical wards with hemoglobin <6.9g/dl,  patients were worked up 
for possible  bacterial, mycobacterial, parasitic and nutritional related causes of  
anemia, which includes bone marrow aspiration.One-third of hiv infected had 
tuberculosis, which diagnosed mainly by bone marrow culture in 8-9% of HIV-
infected patients 53.  
 
   These studies done in the western population show various pathogenic 
organisms comparing to the Indian population. In India the most common pathogenic 
organism causing bone marrow infiltration is most likely  mycobacterium 
tuberculosis. It is observed that TB is  2nd  common opportunistic diseases  in India 
(next to oral candidiasis),  may  also greatly increase the  load of anemia . The 
etiology of anemia in TB is multifactor involvement, leads from a collectively  of 
anemia of chronic disease, bone marrow infiltration and  leads to various lag of 
nutrients such as  selenium, Fe,vitamin and selenium 54  
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MALIGNANCIES  
 
    Malignancies also cause anemia by direct bone marrow infiltration and by 
indirect  means. Bone marrow infiltration of  (NHL) ,Kaposi’s sarcoma, &  Hodgkin’s 
lymphoma are described. The development of lymphoma  the setting of 
Humanimmunodeficiency  infection the mechanisms underlying  fully they are not  
readed. 1 main involvement  may  due to  immune  suppression as own,which on go 
inline along an incline of lymphoma as in particular congenital immunodeficiency 
infection, related autoimmune disorders or in using as immunosuppressive drugs. The 
lymphomas in hiv infected people develop in these settings are same in terms of the 
pathological grade, the increase level of extra nodal infection  reflects presentation, & 
relatively bad outcome. HIV people is associated with a myriad of immunologic 
deficiency. These abnormalities added  chronic involvement  of B lymphocytes 
antigens, mitogens, or viruses, and to  Epstein-Barr virus (EBV), functional & 
quantitative defects of CD4 T cells and HIV  itself. B cell action  and related 
activation lead  to  the development of reactive B cell overactivity  in all  lymphoid 
tissues and also polyclonal hypergammaglobulinemia in  hiv infected  blood. 
Lymphomas  origin  from involvement  of genetic errors while  happening during the 
period of polyclonal B cell multiplication  in the reason of shown  immunodeficiency. 
This finding has been observed in a first  experiment, in that high-grade B cell 
lymphoma observed between five and fifteen  months after hiv diseases  with the 
simian immune deficiency virus, coincident with development of severe 
immunodeficiency55  
 
   In one study says that linked AIDS and cancer entries  in particular parts in  
USA, the relative risk to develops  lymphoma within three  years of an HIV finding  
was increased by 167-times  with compared to people  HIV negative. The same study  
again clearly explains  that the high in risk varies  from 654-times  for high-grade 
diffuse immunoblastic tumors to 262-times  to  Burkitt lymphomas, 114-times for 
intermediate-grade  lymphomas, and 14-times for low-grade lymphomas56  
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FIGURE 10: SEQUENCE OF EVENTS IN LYMPHOMA IN HIV INFECTION 
 
 
                  Although use of HAART happen to show result  to a major and dramatic 
decline in the  new cases of Kaposi sarcoma, results from studies evaluating the effect 
of HAART on the new cases of lymphoma have  inconclusive. The Swiss 
Humanimmunodeficiencyvirus Cohort study & Multicenter  AIDS Cohort Study 
result says no decrease  in the new cases rates of lymphoma within the pre-HAART &  
HAART eras, but the International Collaboration on Humanimmunodeficiencyvirus 
and Cancer and the EuroSIDA studies clearly says with valid decline of lymphoma in 
the HAART era58 . Data from a French study says that who all taking  HAART is 
most  effective in  population the new cases of lymphoma will decline 57 58. Taken 
together, these data suggest that the incidence of AIDS-related lymphoma in a 
population depends on the effectiveness of  HAART is studied with  increasing the 
immune stage of that paticular people. If  HAART is not same type is available or if 
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HAART is ineffective in increasing CD4 counts or decreasing HIV  RNA levels, in 
this condition  the incidence of lymphoma in that population will not be  decline.  
DRUGS.  
 
  More than 22% of all cases of anemia related with 
Humanimmunodeficiencyvirus are may be  drug causing 60. Recognizing that it as the 
specialised side effect is mostly problematic  by on going  disease. Multidrug 
regimens always  alter  things difficult to find  reason for anemia and also   single 
drug may be the main source of anemia and often have an synergistic fedback on bone 
marrow suppression.  
 
    The commonest agents all we used are zidovudine (AZT) & trimethoprim 
sulphamethoxazole. AZT causes most certain  macrocytosis , which may presently  
caused by many as screen to  patient’s treatment with therapy. Bone marrow with 
hypoproliferation & also dysplasia are  seen frequently. Both AZT and d4T cause 
macrocytosis, AZT,  most  myelosuppressive effects seen both in vitro and in vivo29. 
Anemia  treatment  includes with  AZT  which also is used in the treatment  
pneumocystis carinii diseases in HIV is  because of  folate related deficiency & is 
more obvious  over  patients associated poor nutritional thing. Dapsone also with the 
another option was happens to generalized myelosuppression also causes hemolytic 
anemia  
 
Drugs commonly causing myelosuppression in HIV positive patients59  
 
   Anti viral  
? Zidovudine  
? Gancyclovir  
? Zalcitabine  
? Foscarnet  
? Cidofovir  
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Antifungal  
? Flucytosine  
? Amphotericin  
 
Anti Pneumocystis drugs  
? Sulphonamides 
? Pyrimethamine  
? Trimethoprim, 
? Pentamidine 
 
Antineoplastic drugs  
? Cyclophosphamide  
? Doxorubicin  
? Paclitaxel  
 
Immune response modifiers  
        
? Interferon alpha 
 
Zidovudine and anemia  
Anemia in  AZT  reflects  as the  dose dependence  and duration  associated 
and is frequently accompanied with  macrocytosis during bone marrow depression 
due to use of zidovudine is infrequent61 . Inhibition of related thymidine 
monophosphate phosphorylation due to zidovudine monophosphate happens to  
intracellular thymidine triphosphate low level and stem cell observation also be 
observed  due to  the additictive of thymidine. AZT treatment  suppresses the 
proliferation of cells of erythroid, granulocyte/macrophage & primary haematopoietic 
stem cell cultures of  human bone marrow  also causing hypoplasia. Various reasons 
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have been postulated for the hematological effects on zidovudine. Zidovudine may 
decrease the level of  EPO receptor expression & also  function on erythroid 
hematopoietic cells.. AZT particularly inhibits beta globin gene expression to human 
erythroid precursors happening to clearly seen  cell growth inhibition. A toxic 
metabolite 3- amino 3-deoxythymidine  has well noticed  in cultured hepatocytes &  
microsomes which is mostly toxic to BMC  specialy erythroid lines62. Mitochondrial 
toxicity found to be  suggested to take part as incubation  action of the murine 
erythroleukemic cell line of AZT happens  to decrease in action of cell growth &  
inhibition of  oxidative phosphorylation29 .  
 
Use of HAART was found with an incline  in hemoglobin levels 1 year  of 
follow-up (42%)  in a prospective cohort study done in Johns Hopkins university. 
Infected Patients who are not receive HAART theraphy  had a known modest 
increase(31%) in hemoglobin level observed over 1  year of regular follow-up. When 
used  part of a HAART regimen treatment,infected patients who are all receiving 
zidovudine found to be hemoglobin response that was not observed most  
significantly  varies from patients who also had alternate HAART regimens 70    In 
one systematic review (6 RCTs, 1597 people), which found that, over 48 weeks, 
zidovudine  related with a  hemoglobin drop while  hemoglobin rise in people  taking 
stavudine. In all of the RCTs 64  the number of grade 3 or 4 episode of anemia and  
neutropenia was very high with zidovudine when compare with stavudine .Then with 
available witness comparing  zidovudine vs stavudine comes from resource rich 
settings. Strength of the results about equal  benefits and harms are seen,its 
applicability to see poor settings is limited by the fact  that the RCTs included more 
men and fewer other ethnic background  than seen in many resource  poor settings.  
 
                       In a study done in Varanasi India in which patients were followed up 
over a period  of one year 16 hiv patients found  ZDV induced anemia63. This 
comparison found to be very higher to other  reports where the amount of anemia 
varies between 5.6 and 9.9per cent (cut off were 7 and 7.5 g% respectively)65 .All   
Peripheral smear done for those patients showed normocytic, normochromic picture 
in 44 per cent patients and also others featured macrocytic changes. In bone marrow 
examination dysplastic variables were seen in 8 (30%) patients in myeloid line and 7 
(28%)  patients showed dysplastic changes in erythroid line.overall most of the 
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patients with anemia diagnosed  within six  months after  initiation  of therapy was 
resulted  in other studies 66. Two patterns were also noted in the  causative  of 
anemia: (i) progressive fall in haemoglobin in around 60% of patients, and (ii) an  
abrupt fall in haemoglobin in around 40% of patients. In majority of the patients 
(77%), there is well recovery in hemoglobin levels once they stopping zidovudine as 
soon as possible. Eight patients developed anemia after  1 year and in 4 patients 
recovery took as long as 7 months. This process very well explained by the factor that 
myelotoxic effect of drug zidovudine mostly  can persist as long. Risk factors foun 
with zidovudine related anemia reported in various studies supported  advanced HIV 
disease, low body weight, low CD4 counts and low baseline haemoglobin67. .There  
has also been also been case reports of zidovudine causing pure red cell aplasia, 
which was fully  reversible68. In a prospective cohort study done in rural Cambodia 
the odds of developing anemia within 12 months after the switching from stavudine to 
zidovudine were high in patients mostly with CD4 count < 200/mm3 point at the time 
of ZDV starting, in malnourished patients, and in same patients also on co-
trimoxazole prophylaxis while starting  ZDV initiations 69. 
  
   Nowadays mean  zidovudine dosages are much less than those used in 
1980s. According to this study ZDV related  anemia has decreasing trend of less 
likely  and so  comparable Hb  values are also seen  in both  ZDV treated and non 
ZDV treated Humanimmunodeficiencyvirus  patients 71  Most  drugs  are identified of 
increasing ZDV plasma concentrations that also  cause & ZDV toxicity increased. 
Fluconazole and atavaquone directly decrease  ZDV clearance. Chloramphenicol, 
Indomethacin, Naproxen, Ethinylestradiol, Acetylsalicylic acid,  Oxazepam and also 
probenecid can stop liver clearance of zidovudine Furthermore lamivudine also 
increases zidovudine concentration .Liver cirrhosis which is correlate seen in patients 
with HIV/Hepatitis B Virus or HIV/Hepatitis C Virus co infection  very deeply 
involved in  zidovudine metabolism     
  In mice bone marrow, heme exerted a very good protective effect on 
hematopoietic progenitors in vivo and  be of very important clinical use in 
combination with Epo to promote relevant erythropoiesis in the setting of AZT 
therapy73  
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MALNUTRITION  
   Vitamins deficient and other micronutrients is often seen in 
Humanimmunodeficiencyvirus patients. According to Paltiel et al laboratory outcome  
in HIV infected persons shows vitamin B12  as low level  in up to 30% 74. This may 
be due to intestinal malabsorption seen  most commonly in these patients. In a study 
by Matthew et al 13% had at least one low B12 level during the course of their 
infection75. In the study by Rule et al serum B12 in 218 asymptomatic HIV positive  
patients were significantly lower than of a HIV negative control group (P = 0.02). 
Falling CD4 counts were correlating with low vitamin B12 levels in this study76. In 
the study by Burkes et al done in HIV positive patients low B12 concentration was 
not correlating with macrocytosis and parenteral vitamin B12 replaced mostly failed 
to elevate serum cobalamin levels78. This may be because of an early B12 deficiency 
or it may reflect an isolated serum abnormality. While intestinal malabsorption may 
also be contribute for  low cobalamin level, in majority  of patients the  cause is 
notknown. This also be due to altered transcobalamin activity and further studies are 
being done to evaluate low vitamin B12 levels without hematological manifestations77 
Fuchs et al have observed a decreased in  folate level of 27% 79. 
  
 True serum Fe deficiency is often seen in Humanimmunodeficiencyvirus  
patients79 More commonly  decreased serum iron is due to functional block in iron 
release. Bone marrow examination has exposed as  enough or increased  Fe stores 
thus leading to the  Fe usage  in HIV diseases  may also  altered  a functional block in  
iron release.  
Altered iron metabolism in HIV  
     Humans with advanced  (HIV) diseases  present in  some witness  says of Fe 
increased. High  level Fe  may exert negative effects in persons  because of Fe-
mediated oxidative stress. Iron-mediated oxidative stress is mostly  likely involved in  
viral cytopathogenicity. This evidence suggests that Fe  metabolism is an significant  
area for virus & host interaction 80. Large number of patients  in more advanced stages 
of HIV   have more iron deposits in the bone marrow, liver, and also other organs by 
one or more various  several mechanisms.These various ways  added the sequestration 
of Fe upon macrophages with chronic inflammation , a change of Fe  from Hb  in red  
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cells to various macrophage  stores at the time of the development of hypoplastic 
anemia, the transfusion of blood , the increase of Fe acquisition related with ART 
drugs  causing not effective erythropoiesis and a  other types  inherited or acquired 
iron-loading conditions. 81, 82  
 
HEMOLYTIC ANEMIA  
                         In  37% of HIV-infected persons are positive with direct coobs test  
and to have clinically hemolysis is rare 83 This shows  that positive DCT  in HIV-
infection may simply be a result  of polyclonal hypergammaglobulinemia that are 
verycommon in HIV infected people and does not necessarily indicate hemolysis. A 
most of specific and nonspecific antierythrocyte antibodies also been detected in those 
patients. Anti-I, anti-U, anti-E and anti-K  antibodies are more commonly detected 84 
85. One study says  complement receptor induced destruction of red cells by on 
flowing immune complexes 86. With in all  HIV patients with autoimmune hemolytic 
anemia says reduced reticulocyte count quitly interesting87  
 
BLOOD LOSS  
   Gastrointestinal involvement in AIDS may also one of the etiology for anemia 
due to  blood loss . Infections like CMV colitis & malignancies like Kaposi’s sarcoma  
related to  significant anemia and also due to GI blood wastage. In  developing 
countries risk of anemia are may vary from the developed countries in various ways 
like endemic undernutrition, worm infections, TB  and a various spectrum of 
opportunistic diseases. In the study by Subbaraman et al female sex, extrapulmonary 
& pulmonary TB  very highly  independent interlink with anemia. Age  more than 
tnirteen one  years, oral,oesophageal candidiasis & generalized lymphadenopathy had 
independent risk factor with anaemia3 Three of various influencial things associated 
with anemia – TB, immunosuppression and undernutrition – shows  each other in 
synergistic manner. The final  result is  vicious cycle seen in  HIV positive patients in 
TB-endemic countries at very  high risk  anemia to develop.  
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TREATMENT  
  The diagnostic approach to anemia in Humanimmunodeficiencyvirus  
infected subjects were also be performed with other causative  conditions. However 
the treatment of anemia in HIV  positive  patients to differ from HIV negative persons 
as the etiologies may differ especially in patients  with severe immunodeficiency. The 
clinical workup  say HIV diseased  patients with anemia  must be include an attempt 
to rule out all correctable causes of anemia . After correction of the underlying 
cause(s) the management of anemia typically includes and blood transfusion or  
erythropoietin.  
 
Treatable causes of anemia in HIV positive patients89  
• Nutritional deficiencies(malnutrition/malabsorption)  
• Anemia of chronic disease  
• Myelosuppresive drugs  
• Vitamin B12,iron or folate deficiency  
• Neoplasia(eg Non Hodgkins lymphoma) 
• Oppurtunistic bone marrow infections  
HAART.  
                HAART gives result to very well  improvement of various anemia. A 
different results from   the WIHS study says that HAART  found  crucially related 
with  anemia to corect; outcome was noted around  six  months, and a major  
resolution occurred long time intake of a  HAART use (P <.0001) 90. In the setting of 
a generalized HIV epidemic HIV-complicated anemia requires a various approach. 
HAART can  be initiated  for the anemia if no reason is identified for cause 95. The 
2010 revision of the WHO guidelines for resource-limited  strongly  recommend to 
start ART with a particular regimen wih  zidovudine or tenofovir in  joining with 
lamivudine & a non-nucleoside reverse transcriptase inhibitor, because of toxic effect 
due to  long-term toxicities of stavudine97  
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BLOOD TRANSFUSION  
   Therapies like anti-anemic increase the effect of HIV disease. Blood 
transfusions also reasons to have also useful as  immunomodulatory effect by up 
regulation of  humoral immunity and downregulating cellular immunity. Blood 
transfusions may also  happen to decline in  T helper type1 & increased T helper type 
2 cytokine production as well as increased CD 8 cells and decreasd CD4 cells91  
 
ERYTHROPOIETIC AGENTS  
         In multiple controlled and uncontrolled study shows results, epoetin alfa action 
shows effective and important role for the  anemia treatment in HIV infection. 
Epoetin alfa marked improved hematocrit values (P=0.05) in persons with HIV and  
are all taking zidovudine, with endogenous erythropoietin levels of <500 IU/ L. An 
incline  11 g was seen by a week 2, furthers increase the level of 12 g by week 4. 
Treatment found to be related with marked reductions in blood transfusion 
requirements (P<0.003) and aberrantly increase the overall quality of life 92 93. 
Increased with levels of proinflammatory cytokines, EPO show little set back in poor 
response in anemia ,one side  and decrease Fe  availability on  other side . In clinical 
terms, corrected reticulocyte counts are used more to know the response of EPO level 
and also potential response and not responding. However in comparison with placebo 
human recombinant EPO no change in mortality, no change in blood  transfusion 
requirements, not increase Hb values and same not good outcome with  quality of life 
for HIV positive persons  with anemia according to the Cochrane review done based 
on six trials 96. Therefore prescription for human EPO for  anemia to treat   in HIV  
patients is not approved  unless,  high quality trial is not alters this results with no 
other new evidence results found .  
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FIGURE 11: GUIDELINES FOR ERYTHROPOIETIN IN HIV POSITIVE 
PATIENTS94 
 
 
 
  In addition to role of HAART, other  supportive &  TB control should be the good 
work for  anemia management for HIV  individuals in India88. Strongest factors are 
three thing with anemia – TB, immunosuppression and undernutrition – all exacerbate 
one other in same manner. The overall  result is a vicious cycle placing HIV- patients 
in Tuberculosis-endemic countries at more risk for complication of anemia.. Low 
Body Mass Index is are also related with many micronutrient deficiencies – including 
Fe, folate and B12 – that contribute  directly to anemia.  
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FUTURE TRENDS  
    Pro inflammatory cytokines TNF alpha and IL beta possibly happens to 
decreased renal erythropoietin synthesis. Interventional  studies with substances that 
have stop release of proinflammatory cytokines such as pentoxyphylline  have no 
response to treat the anemia inducing effects.98 Future work up  should focus on to 
understand  various  reasons  of anemia, long-term result to give results and 
prognostic values, the results of various HAART regimens  the overall case load of 
anemia, and valuable dosing are strategies to treat with  epoetin alfa in  all type of 
special group of people. Emerging data shows results as that epoetin alfa has valid  
effects   more than erythropoiesis. There is also evidence, for evidence, that epoetin 
alfa also has antiapoptotic  effects in various  multiple cell lines,and also  helpful in 
way of all have a good  impact on the immune response in  individuals with HIV 
infection . 
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4. METHODOLOGY 
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SETTING  
              This was a descriptive cross-sectional study done during the period of April 
2016 to September 2016 on 60 consecutive HIV patients in different stages of disease 
seen as inpatients in  medical ward MADRAS MEDICAL COLLEGE (MMC), 
CHENNAI, TAMIL NADU, INDIA.  
All respondents were adults, aged more than 18 yrs. Informed consent was 
taken prior to  inclusion in the study.  
 
PATIENTS  
            Patients were selected on an in-patient basis in medical ward. The in-patients 
were those who were admitted to the medical wards of MMC  during the 
aforementioned period 
 
INCLUSION CRITERIA  
         HIV positive patients  
         Anemia with hemoglobin less than 10.9gm/dl  
 
METHOD OF COLLECTION OF DATA  
         All patients were interviewed and examined by the investigator. A Proforma, 
which is    appended in the annexure, was used for the above purpose.  
 
TESTS  
  HIV was confirmed by the ELISA test. CD4 counts were analyzed using the 
Flowcytometry method. Hemoglobin, total count and differential count were 
performed in the  laboratory using automated counting chambers and confirmed 
manually. Further work up for  anemia including reticulocyte count, peripheral smear 
examination, mean corpuscular volume estimation, direct coombs test, serum ferritin 
and B12 levels were done. Bone marrow aspiration   was done for most of the patients 
as part of anemia evaluation. Other tests were done as per the  needs of the patient.  
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STATISTICAL METHODS  
  Statistical analyses was performed with SPSS. Normal data were summarized 
using  mean and standard deviation (SD) and non-normal data using median and 
interquartile range.  Correlation coefficient was be used to compare hemoglobin 
values and CD4 counts. 
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5. RESULTS 
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DEMOGRAPHY 
Table:2 AGE DISTRIBUTION 
AGE_GROUP FREQUENCY PERCENT 
20 - 30 YEARS 9 15.0 
31-40 YEARS 17 28.3 
41 - 50 YEARS 27 45.0 
51-60 YEARS 7 11.7 
Total 60 100.0 
 
Table : 3 AGE DISTRIBUTION 
Descriptive 
Statistics 
N Minimum Maximum Mean Std. Deviation 
AGE 60 22.00 60.00 41.2333 8.52785 
 
Chart : 1 AGE DISTRIBUTION 
 
SIXTY PATIENTS WITH HIV INFECTION AND ANEMIA WERE INCLUDED 
IN THE STUDY.MINIMUM AGE WAS 22 YEARS AND MAXIMUM AGE WAS 
60 YEARS ( MEAN+SD: 41.23+8.52) 
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Table :6 MEAN IN AGE 
AGE MEAN STANDARD DEVIATION 
FEMALE 38.39 9.25 
MALE 42.45 8.01 
Total 60 100.0 
 
Chart :4 
 
MEAN IN AGE  + SD FEMALE (38.39 +9.25) MALE (42.45+ 8.01) 
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Crosstab 
Table : 21 CORRELATION BETWEEN CD4 COUNT AND 
Se.B12 
 
CD4 COUNT  AND B12 LEVEL CD4COUNTS Total 
<200 >200 
S.B12 
L 
Count 7 2 9 
% within 
CD4COUNTS 20.0% 8.0% 15.0% 
N 
Count 28 23 51 
% within 
CD4COUNTS 80.0% 92.0% 85.0% 
Total 
Count 35 25 60 
% within 
CD4COUNTS 100.0% 100.0% 100.0% 
Pearson Chi-Square t = 1.647 p= 0.199 
 
Table : 22 Crosstab 
CD4 COUNT AND S.FERRITIN CD4COUNTS Total 
<200 >200 
S.FERRITI
N 
< 24 
Count 2 0 2 
% within 
CD4COUNTS 5.7% 0.0% 3.3% 
> 24 
Count 33 25 58 
% within 
CD4COUNTS 94.3% 100.0% 96.7% 
Total 
Count 35 25 60 
% within 
CD4COUNTS 100.0% 100.0% 100.0% 
Pearson Chi-Square  t =1.478 p=0.224 
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Group Statistics 
Table : 23 CORELATION BETWEEN   Hb and ART 
 ART N Mean Std. Deviation Std. Error Mean 
Hb 
NO 24 8.4625 1.51910 .31008 
YES 36 7.7250 1.26092 .21015 
t=2.044* p=0.045 
 
Chart : 19 
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Table : 24 CORRELATION BETWEEN   Hb and ZDV 
ZDV FREQUENCY PERCENT 
N 16 45% 
Y 20 55% 
Total 36 100.0 
 
Chart :20 
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Table : 25 CORRELATION BETWEEN MCV AND ART 
 
 ART N Mean Std. Deviation Std. Error Mean 
MCV 
NO 24 85.21 7.656 1.563 
YES 36 94.83 17.958 2.993 
t=2.475 *  p=0.016 
Chart : 21 
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Table : 26 CORRELATION BETWEEN MCV AND ZDV 
 
 ZDV N Mean Std. Deviation Std. Error Mean 
MCV 
YES 20 97.55 18.785 4.201 
NO 16 91.44 16.832 4.208 
t=1.015 p= 0.317 
 
ANEMIA  AND OTHER FACTORS 
Table : 27 CORRELATION  BETWEEN SEX AND  Hb 
Group Statistics 
 
 SEX N Mean Std. Deviation Std. Error Mean 
Hb 
MALE 42 7.8119 1.41804 .21881 
FEMALE 18 8.5056 1.28451 .30276 
t=1.784 p= 0.08 
 
 
 
Table 28 Group Statistics  ETIOLOGY AND Hb 
 
 ETIOLOGY N Mean Std. Deviation Std. Error Mean 
Hb 
OTHERS 29 8.2966 1.51221 .28081 
INFLAMMATION 31 7.7613 1.26798 .22774 
t=1.489  p= 0.142 
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CD4 COUNT AND ANEMIA 
Table : 29 CD4  COUNT AND HEMOGLOBIN 
 CD4__COUNTS N Mean Std. Deviation Std. Error Mean 
Hb 
<200 35 7.6657 1.15248 .19480 
>200 25 8.5160 1.59235 .31847 
t=2.042*  p=0.02 significant 
Chart : 22 
 
THERE IS SIGNIFICANT DIFFERENCE IN HEMOGLOBIN VALUES AMONG 
PATIENTS WHO HAD CD4<200 AND  CD4 > 200. 
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Table : 31 ETIOLOGY OF ANEMIA 
ETIOLOGY FREQUENCY PERCENT 
Anemia chronic disease (inflammation) 31 51.7 
Anemia secondary to bone marrow infiltration 6 10.0 
Iron deficiency anemia 6 10.0 
B12/Folate deficiency anemia 9 15.0 
Zidovudine Induced anemia 6 10.0 
Anemia secondary to hemolysis 2 3.3 
Total 60 100.0 
 
Chart : 24 
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Hypoproliferative anemia’s is characterized by low reticulocyte 
production index normocytic, normochromic red cells, although microcytic, 
hypochromic cells may be observed. Causes are (1) marrow damage, (2) iron 
deficiency, (3) inadequate EPO stimulation- impaired renal function, suppression of 
EPO production by inflammatory cytokines such as interleukin 1, or reduced tissue 
needs for O2 from metabolic disease such as hypothyroidism  
Maturation defect is characterized by low reticulocyte production index, 
macro- or microcytosis on peripheral blood smear. Bone marrow examination shows 
erythroid hyperplasia. Causes are nuclear maturation defects, associated with 
macrocytosis and abnormal marrow development or cytoplasmic maturation defects, 
associated with microcytosis and hypochromia usually from defects in hemoglobin 
synthesis.  
Hemolytic anemia is characterized by increased reticulocyte 
proliferation index.  
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CD4 COUNTS AND OTHER PARAMETERS CORRELATION 
Table : 32  CD4 COUNT AND ETIOLOGY OF ANEMIA 
CD4 COUNT 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
Minimum Maximum 
Hypoproliferative 
Anemia 
45 158.0667 102.63293 15.29961 50.00 608.00 
Maturation defect 13 281.7692 202.17078 56.07209 18.00 658.00 
Hemolysis 2 270.0000 212.13203 150.00000 120.00 420.00 
Total 60 188.6000 140.64033 18.15659 18.00 658.00 
t= 4.794*p=0.012 
 
Chart : 25 
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Table : 33 CD4 COUNTS AND VARIES FACTORS OF  ANEMIA 
 
GROUP STATISTICS 
CD4 COUNT 
ETIOLOGY N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Anemia chronic 
disease 
(inflammation) 
31 154.0000 99.86457 17.93621 
OTHERS 29 225.5862 168.08066 31.21180 
t= 2.021* p=0.048 
Chart : 26 
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Table : 34 CD4 COUNT AND FUNCTIONAL CLASSIFICATION OF 
ANEMIA 
CD4 COUNTS  
 ETIOLOGY FUNCTION  
 Cross tabulation 
ETIOLOGY FUNCTION 
Total 
Hypoprolife
rative 
Anemia 
Matura
tion 
defect 
Hemolys
is 
CD4 COUNTS 
<200 
Count 27 7 1 35 
% within 
Etiology_Function
60.0% 53.8% 50.0% 58.3% 
>200 
Count 18 6 1 25 
% within 
Etiology_Function
40.0% 46.2% 50.0% 41.7% 
Total 
Count 45 13 2 60 
% within 
Etiology_Function
100.0% 100.0% 100.0% 100.0%
 
Chart : 27 
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Table : 35 CD4 COUNTS AND VARIOUS ANEMIA CORRELATION 
 
 
 
 
 
 
 
 
 
 
CD4 COUNTS * 
ETIOLOGY 
Crosstabulation 
ETIOLOGY 
Total 
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chronic 
disease 
(inflammatio
n) 
Anemia 
secondary 
to bone 
marrow 
infiltration 
Iron 
deficienc
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B12/Fola
te 
deficienc
y anemia 
Zidovudi
ne 
Induced 
anemia 
Anemia 
seconda
ry to 
hemolys
is 
CD4 
COUN
TS 
<200 
Count 21 3 4 5 2 0 35 
% 67.7% 50.0% 66.7% 55.6% 33.3% 0.0% 58.3%
>200 
Count 10 3 2 4 4 2 25 
% 32.3% 50.0% 33.3% 44.4% 66.7% 100.0% 41.7%
Total 
Count 31 6 6 9 6 2 60 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
100.0
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In this study 60 consecutive patients infected with HIV (42 males and 18 
females) and anemia who were admitted to the medical wards were included. Patients 
with mild anemia (>10.9g/dl) were excluded from the study. Only patients with 
hemoglobin less than 10.9 gm/dl (more than grade one of WHO/ACTG criteria) were 
included in the study29.  
DEMOGRAPHY  
Minimum age of the subjects was 22 years and the maximum age was 60 years 
(Mean ± SD: 41.23±8.52). 70%  of the subjects were male and 30% were female. 
Mean age in males was 42.5(SD 8.8) years and in females was 39 (SD 8.0) years. The 
disease was seen affecting people in the most productive years of their live. These 
demographic data are similar to those documented in other studies done in India88. 
88.3% percent of patients were married. The unmarried patients (11.7% of the total) 
were all males. Males have commonly acquired the disease through premarital and 
extramarital sexual contact, whereas females have mostly acquired the disease from 
their spouses. Females have generally been diagnosed as HIV positive during either 
routine or ante natal checkups or when their husbands came with opportunistic 
infections. Majority of our study population were from tamil nadu  and adjoining part 
of Andhra Pradesh. Madras medical college  is a major referral center for patients 
from these areas. Patients from Tamil Nadu and part of Andhra  utilize the services of 
this hospital and the study can be considered as done in a South Indian population. 
FEATURES OF PATIENTS WITH HIV AND ANEMIA  
Among the patients in the study 81.3%had their diagnosis established within 1 
year of this study and 18.7% had their diagnosis established greater than one year ago. 
This was much lesser compared to other standard studies99. The mean CD4 count was 
193/μl. Mean CD4 count in males was 199/μl and in females was 200/μl. CD4 count 
was lesser than 200/μl in 58.3% of patients and was greater than 200/μl in 41.7% of 
the patients. These features were similar to the other studies done in South India. 99 
Thus the patients included in this study had advanced disease. 60% percentage of the 
patients were on HAART. Among the patients on HAART 67% were on zidovudine 
and the remaining 33% were on stavudine along with lamivudine and an NNRTI. 
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There were no patients on any other NRTI. 75% of the total patients were on co- 
trimoxazole therapy.  
Severity of anemia was classified according to ACTG/WHO grading. 16.7%  
had grade one, anemia, 31.7% had grade two,18.3% had grade threen and 33.3% had 
grade four anemia. This was in contrast to a study done by Owiredu et al100 in an ART 
clinic in Ghana in which more patients were found to have grade one and two anemia 
in comparison to grade four anemia. (Grade one and two- 76%; grade three – 19%; 
grade four - 7%). This is probably because our study was done in a tertiary care 
hospital and majority of the patients had advanced disease and higher grades of 
anemia. Among our patients 53.3% had associated leucopenia and 11.7 % had 
associated thrombocytopenia. The prevalence of neutropenia ranges from 0.8% to 
44% and thrombocytopenia ranges from 8% to 30% in patients with HIV according to 
other studies done by Zon et al and Murphy 77 et al 101 102 The mean of mean 
corpuscular volume(MCV) was 89.2fl (Range 59-125fl). Seventy percent had their 
MCV in normal range. Sevnteen percent had MCV less than 76 fl and 13% had MCV 
greater than 96 fl. This is similar to the study done by Tripathi et al which showed 
normal MCV in 88.5 %, low MCV in 6.56 % and high MCV in 4.92 % of patients32. 
Sixty percent of patients with MCV less than 76 fl had iron deficiency anemia. Thus 
40% of patients with low MCV had etiology of anemia other than iron deficiency & 
microcytosis cannot be taken as indicative of iron deficiency. Among the patients 
with macrocytosis 87.5% had B12/folate deficiency and 12.5% had zidovudine 
induced anemia. Macrocytosis is commonly attributed to NRTI therapy but in our 
study majority of these patients had a low levels of vitamin B12 or folic acid. 
96.7%of  patients had reticulocyte proliferation index (RPI) less than 2.5. The 
mean RPI was 0.71(Range 0.03- 4.40). This indicates that majority of these patients 
have hypoproliferative marrow due to various causes. 
15 %of the patients had positive direct antiglobulin (Coomb’s) test (DCT). 
However, only 3% had evidence of hemolysis (high lactate dehydrogenase levels; 
unconjagated hyperbilirubinemia). This finding is similar to the results of another  
study by Ellaurie et al which showed DCT positivity in 37% of HIV- persons but 
clinically  not significant hemolysis 83. This indicates that positive DCT in HIV 
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infection may simply be a results of polyclonal hypergammaglobulinemia which is 
common in HIV infection & may not necessarily mean hemolysis.84 87 78. 
FERRITIN AND B12 LEVELS  
In our study 15% had low vitamin B12 levels. According to Paltiel et al  
laboratory findings in HIV sero positive individuals shows  vitamin B12 decreased  in 
up to 30% 74. In a study by Matthew et al 13% had at least one low B12 level during 
the course of their infection 75. In a study by Rule et al serum B12 in 218 
asymptomatic HIV positive patients were significantly lower than of a HIV negative 
control group (P = 0.02). Falling CD4 counts were correlating with low vitamin B12 
levels in this study. 76 However in our study there was not significant relation  between 
vitamin B12 levels and CD4 count  or Hb . In the study by Burkes et al done in HIV 
positive patients low B12 concentration was not correlating with macrocytosis and 
parenteral vitamin B12 replacement  often failed to increase  serum cobalamin levels. 
77 78 In our study only 50% percentage of patients with low B12 levels had 
macrocytosis & absence of macrocytosis cannot be used to rule out B12 deficiency. 
While underabsorption is on &b off  responsible for the low  level cobalamin, in most 
patients  the cause is notknown and may show  a serum abnormality. This may be due 
to altered transcobalamin activity and further studies are being done to evaluate low 
vitamin B12 levels without hematological manifestations77  
3.3%had low ferritin levels. In our study there was no related  correlation 
between serum ferritin levels and CD4 count  or hemoglobin . Even in the presence of 
absolute iron deficiency serum ferritin levels may be elevated in HIV infection 
because of chronic inflammation. Though 10% of patients in our study had absolute 
iron deficiency manifested by grade zero iron stores in the bone marrow only. 3.3%of 
patients had low serum ferritin levels. All patients with low ferritin levels had iron 
deficiency. Thus normal ferrtin level does not rule out iron deficiency in HIV positive 
patients as ferritin is known as  acute phase reactant & gets increased  in 
inflammatory states. 
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Most patients in our study had high serum ferritin levels. Riera et al reported a 
high prevalence of elevated serum and red cell ferritin levels in 168 patients with HIV 
infection. High serum ferritin levels were found to correlate with clinical worsening 
of infection and with decreasing CD4+ lymphocyte counts (p < 0.001) in this study.103  
PERIPHERAL SMEAR AND BONE MARROW EXAMINATION  
In peripheral smear examination, 78% of the patients had normocytic 
normochromic anemia. Microcytes were present in 22% and 20% had macrocytes. 
There was a minimal discrepancy between the values obtained on measurement of 
MCV & the impression of the pathologist on the peripheral smear. 
Anisopoikilocytosis was noted in 60%. Tear drop cells were seen in 40% of patients. 
In the study by Jam et al RBC  morphology  readed as  macrocytosis in 11%, 
normocytosis in 41.1% and microcytosis in 47.9% of the patients.104 Erythrocyte 
morphology is  described as normal and also  abnormalities such as anisocytosis 
poikilocytosis, rouleaux formation have been reported2  
Bone marrow was particularly examined for cellularity, dysplasia, and 
fibrosis, infiltration by infectious agents or malignant cells and iron staining. 
Common histopathological features, suggestive of HIV infection but non-
pathognomonic as reported in other studies were hypocellularity, dysplasia, and 
lymphocytic and histiocytic infiltrates with or without granulomas, reticular fibrosis 
and increased iron deposits. 105  
According to Hoffman et al dysplastic changes were seen in 30% patients in 
myeloid line and 28% showed dysplastic changes in erythroid line.66 Dysplasia may 
manifest as megaloblastic change. In our study 87% had normocellular and 13% were 
found to have hypocellular marrow. 85% percent had normoblastic maturation and 15 
% had megaloblastic maturation. 25% had dysplastic changes in bone marrow. 
Hypocellularity in bone marrow in HIV positive patients range from 6.75% according 
to Tripathi et al to 34% according to Xiaohui et al respectively. 32 33 In our study 
among patients with hypocellular marrow 75% had CD4 count less than 200. As 
reported by Marche et al hypocellularity in bone marrow is usually associated with 
severe immunodeficiency105  
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ETIOLOGY OF ANEMIA  
In terms of functional classification, 75% had hypoproliferative anemia. 
21.7% had maturation defects. 3.3% had anemia secondary to hemolysis. The largest 
number of patients had anemia of chronic disease in comparison to other etiologies. 
51.7% had anemia of chronic disease, 10% had anemia secondary to bone marrow 
infiltration, 10% had iron deficiency anemia, 15% had B12/folate deficiency, 10% 
had anemia secondary to use of zidovudine, and 3.3 % had anemia due to hemolysis. 
Among the patients who had bone marrow infiltration, 33.3% (n=2) had tuberculosis 
and 66.6 % (n=4) had lymphoma.  
Among the four patients who had lymphoma one patient had high grade T cell 
lymphoma and three patients had low grade B cell lymphomas. The relative risk of 
developing lymphoma is high in people with AIDS. In a study by Kote et al, the 
incidence of lymphoma increased by 165 fold in people with AIDS within 3 years of 
diagnosis compared to people without AIDS.56 The increase in risk ranged from 652-
times  for high-grade diffuse immunoblastic tumors to 14-times  for low-grade 
lymphomas.56 In our study all the patients with lymphoma had CD4 count < 200. 
Studies have documented a definite correlation between the CD4 count and incidence 
of lymphoma. The risk of NHL is greatly increased with low CD4 counts. According 
to Bhaskaran et al106 the relative risk of NHL increased to 6.3 at CD4 cell counts <  
200/μl in comparison to patients with CD4 count greater than 350/μl. This 
corresponds to the details in the EuroSIDA studies which state that there is a decline 
in incidence of lymphoma in the HAART era (with improvement in immune status) 
comparing to the pre-HAART era.58 In our study in 2% of patients bone marrow 
examination revealed a diagnosis of tuberculosis. In a prospective study done by 
David et al 53 in 105 adults with HIV infection and anemia 33% of patients had 
tuberculosis. It was diagnosed only by bone marrow culture in 8% of patients. As TB 
is the 2nd  common opportunistic diseases  in India (next to oral candidiasis), it may 
greatly increase  the burden of anemia in this population. This underscores the 
importance of bone marrow examination in the evaluation of anemia in these patients, 
especially in patients with CD4 count  less than 200/μl 88.  
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CD4 COUNT AND ANEMIA  
An attempt was made to look for any relationship between immunological 
status as indicated by CD4 count and anemia as indicated by hemoglobin levels. 
Many prospective and cross sectional studies have shown a good correlation between 
Hb and CD4 counts. In resource poor settings, hemoglobin could be used as a 
surrogate marker for CD4 count for monitoring of disease progression according to a 
study by Christian et al done in Ghana. This showed there was a significant and 
positive interpretation  (r2 = 0.1755; p < 0.0001) between the blood hemoglobin level 
and their respective CD4 counts 107. This association is most likely explained by fact 
that disease progression could be associated with cytokine mediated 
myelosuppression. However various factors not related to disease progression may 
interfere in the direct relationship between CD4 count and hemoglobin including 
antiretroviral therapy, blood loss etc. and need to be excluded as in the above study. 
There may be no correlation between hemoglobin and anemia if all the etiologies of 
anemia are included as in our study. 
There was no relevant  difference in Hb  values among patients who had CD4 
count <  200/μl (mean Hb 5.65gm/dl) and CD4 count greater than 200/μl (mean Hb 
5.54gm/dl) (p=0.892). There was  relation  between CD4 count and hemoglobin 
(r=0.089, p=0.02) in our study. There  was similar to the findings of a study done by 
Seyed et al in Iran which showed poor correlation (R =0.451, P = 0.056) 108 As there 
was lack of correlation between hemoglobin and CD4 count further statistical analysis 
was done to look for relation between CD4 count and etiology of anemia. 
Mean CD4 (119/μl) in patients who had anemia of chronic disease is 
significantly lesser than  mean CD4 (270/μl) in patients who had anemia due to other 
etiologies (p<0.001). Among patients with low immunological status as expressed by 
CD4 count less than 200/μl, the etiologies of anemia were anemia of chronic disease 
(51.7%), anemia secondary to bone marrow infiltration (10.0%), B12/folate 
deficiency and zidovudine induced anemia (25%). In patients with CD4 count greater 
than 200/μl, the most common etiologies of anemia were iron deficiency (26.1%), 
Vitamin B12/folate deficiency and zidovudine induced anemia (39.1%), anemia of 
chronic disease (26.1%) & anemia secondary to hemolysis (8.7%). There were no 
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cases of anemia secondary to bone marrow infiltration. All patients with bone marrow 
infiltration had CD4 count <  200/μl, and thus bone marrow examination was very 
important in patients with low CD4 count. In patients with CD4 count >  200/μl, 
anemia in  chronic disease was less common and other etiologies were comparable to 
HIV negative patients.  
CD4 COUNT AND OTHER FACTORS  
In our study there was significant difference in the bone marrow iron staining 
among patients with low immunological status as expressed by CD4 count <  200/μl, 
in comparison with persons  having CD4 count greater than 200/μl. Among patients 
with CD4 count <  200/μl, eighty six percentage of patients had more than normal 
marrow iron staining in macrophages (grade 4 to 5) whereas in patients with CD4 
count >  200/μl, only fifty six percentage had high bone marrow iron stores. 
(p=0.002). This is similar to other studies which show that increased bone marrow Fe 
stores are found in patients with severe disease. In a study by Cecile et al81, three 
hundred and forty-eight HIV positive patients were analyzed for the involvemant of 
Fe stores on survival. Patients with grades 4 to 5 Fe  stores ( increased) were 
compared to those with grades 0–2 Fe stores (normal ). In this study there was severe 
immunodeficiency in patients with high macrophage iron .81 A large study from 84 
Gambia found that increased  iron status was associated with increased mortality in 
HIV positive patients. 109 Iron supplementation in HIV positive patients without 
evidence of true iron deficiency may be harmful since excessive iron accumulation is 
associated with enhanced oxidative stress and progression of HIV infection 82  
DRUGS AND ANEMIA  
According to Moinuddin et al60 >  20% of cases of anemia associated with 
HIV are drug causing. Recognizing this like  specific side effect is usually 
problematic  by the fact that progressive disease, opportunistic infections & bone 
marrow infiltration can all cause anaemia in these patients, in addition to other usual 
causes seen in non-HIV infected patients. Additionally, many patients are on multiple 
drugs and to determine the effect of individual drugs can be difficult. Most 
prospective studies in Europe and North America have reported that ART is 
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associated with resolution of HIV-associated anemia. 70 110 111. A study from rural 
Uganda found that the mean Hb increased from 11.3 g/dL at baseline to 12.8 g/dL 
after twelve  months on ART.112. 
In our study mean hemoglobin of patients on HAART (5.58 gm/dl) was found 
to be low comparing to people not on HAART (7.52 gm/dl). (P<0.001). However, this 
cannot be interpreted as HAART causing anemia because there has been a pre-
selelection to include only patients with grade I -IV anaemia, patients on HAART 
would obviously have had more advanced disease, the numbers were too small to 
correlate the hemoglobin levels with the duration of HAART & patients were not 
longitudinally followed up as this was a cross-sectional study. It is well documented 
that other than when there is drug induced anaemia, HAART is associated with 
progressive improvement in anaemia.  
There was significant difference in the hemoglobin levels in patients on 
zidovudine (5.54gm/dl) and non-zidovudine regimens (6.98 gm/dl) . 27% of patients 
on zidovudine had zidovudine induced anemia. In a prospective study done in 
Varanasi India in which patients were followed up over a period of one year 16.2 
patients developed ZDV induced anemia63. In most patients, anemia developed within 
six  months of start of therapy as seen  in other studies. 66 In most of the patients 
(77%), there was a sharp recovery in hemoglobin levels after stopping zidovudine 
within a month. Peripheral smear examination in this study showed normocytic, 
normochromic picture in 42 per cent patients and others showed macrocytic changes. 
In our study 37.5% had normocytic, normochromic picture and others showed 
macrocytic changes.  
In our study, the mean mean corpuscular volume was significantly higher in 
patients on ART (91.9 fl) compared to patients not on ART (84.2 fl).  There is no 
significant difference in the mean MCV in patients on zidovudine (92.11fl) &  non-
zidovudine (91.51fl) regimens. (P=0.922). In a study by Moyle et al both AZT and 
d4T induce macrocytosis.29 Macrocytosis can be expected in patients on either of 
these two drugs.  
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ANEMIA AND OTHER FACTORS  
In our study, the mean hemoglobin was significantly higher in newly 
diagnosed patients (7.34 gm/dl) compared to patients who had been diagnosed earlier 
(6.44 gm/dl). Many of the newly diagnosed patients were probably in a less advanced 
state of the disease. Drug induced anaemia could have also contribute to this. It could 
also be artifactual as only patients with mild, moderate or more severe anaemia have 
been included .  
There was no association between hemoglobin and gender. There was no relevant  
difference in the mean hemoglobin levels among various functional causes of anemia. 
The mean hemoglobin levels did not significantly differ among various etiologies of 
anemia.  
 
LIMTATIONS OF THE STUDY  
• The study has a few limitations that needs to be mentioned  
• The number of cases studied was 60. This number is much smaller than the 
numbers studied in many major studies  
• The study was a cross sectional one with minimal follow up due to time 
constraints. This did affect serial monitoring of patients.  
• There is a selection bias. A greater proportion of patients with low CD4 counts 
have been included in the study as it has been done in a tertiary care center.  
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7. CONCLUSION 
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In this study, sixty patients with HIV infection and anemia were studied to 
find the etiology of anemia in HIV  infected patients and  find the relationship between 
anemia and immunological status as mention  by the CD4 count. Only patients with Hb 
less than 10.9 g/dl (more than grade I of WHO/ACTG criteria) were included in this 
study.  
Mean age of the patients was 40.97 years and the disease was seen 
affecting  people in the most productive years of their life. Majority of the subjects were 
men (73%).  
CD4 count was lesser than 200/μl in 58% of patients and was greater than 
200/μl in 42% of the patients. Thus the patients included in this study had advanced 
disease. Mean CD4 count in males was 199/μl and in females were 200/μl.  
Sixty  percent of the patients were on HAART. Among the patients on 
HAART 67% were on zidovudine and the remaining 33%were on stavudine along with 
lamivudine and an NNRTI. 
16.7% had grade oneanemia,31.7%  had grade two anemia, 18.3% had 
grade three and 33.3% had grade four anemia. This is probably because our study was 
done in a tertiary care hospital and majority of the patients had advanced disease. 
Fifty three percent had associated leucopenia and 11.7% had associated 
thrombocytopenia.  
Seventy percent had their MCV in normal range. Seventeen percent had 
MCV less than 76 fl and 13% had MCV greater than 96 fl. On peripheral smear, 68.3%  
of the patients had normocytic normochromic anemia. Microcytes were present in 13.3% 
and 13.4% had macrocytes. Peripheral smear is more sensitive than MCV in the 
evaluation of anaemia.  
Sixty percent of patients with MCV less than 76 fl had iron deficiency 
anemia. Forty percent of patients with low MCV had etiology of anemia other than iron 
deficiency. Among the patients with macrocytosis 87.5% had B12/folate deficiency and 
12.5% had zidovudine induced anemia. 
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Ninety seven percent of the patients had reticulocyte proliferation index 
(RPI) less than 2.5. This indicates that majority of these patients have hypoproliferative 
marrow due to various causes.  
Fifteen pecent of the patients had positive direct antiglobulin (Coomb’s) 
test (DCT). However, only 3% had evidence of hemolysis. This indicates that positive 
DCT  in HIV infection may not necessarily mean hemolysis. 
Thirteen percent  had low vitamin B12 levels. However only 50% percent 
of patients with low B12 levels had macrocytosis.  
Ten percent of patients in our study had absolute iron deficiency , 
however only half of these patients had low serum ferritin levels. Thus a normal ferritin 
level does not rule out iron deficiency in HIV positive patients. 
In bone marrow examination, 87% had normocellular and 13% were 
found to have hypocellular marrow. Eighty five percent had normoblastic maturation and 
15 % had megaloblastic maturation. 25% had dysplastic changes in bone marrow. 
Among our patients with hypocellular marrow 75% had CD4 count less 
than 200/μl.  
The largest number of patients had anemia of chronic disease in 
comparison to other etiologies. Fifty two percent had anemia of chronic disease, 15% had 
B12/folate deficiency, 10% had bone marrow infiltration, 10% had iron deficiency 
anemia, 10% had zidovudine induced anemia and 3% had anemia due to hemolysis. 
Among the patients who had bone marrow infiltration (n = 6), 33.3% (n 
=2) had tuberculosis and 66.66% (n = 4) had lymphoma. All the patients with lymphoma 
had CD4 count less than 200/μl. In one of the patients who had tuberculous infiltration of 
the marrow, this was the only evidence of tuberculosis  
There was no relevant difference in Hb  values among patients who had 
CD4 count < 200/μl (mean Hb 5.65gm/dl) and CD4 count greater than 200/μl (mean Hb 
5.54gm/dl) (p=0.897). There was no relation between CD4 count and hemoglobin 
(r=0.089, p=0.498).  
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However, mean CD4 count (119/μl) in patients who had anemia of 
chronic disease was significantly lesser than the mean CD4 count (270/μl) in patients who 
had anemia due to other etiologies (p<0.001). 
Among patients with low immunological status as expressed by CD4 
count less than 200/μl, the etiologies of anemia were anemia of chronic disease (67.6%), 
anemia secondary to bone marrow infiltration (16.2%) B12/folate deficiency and 
zidovudine induced anemia (16.2%). Among patients with CD4 count greater than 200/μl, 
the etiologies of anemia were iron deficiency (26.1%), Vitamin B12/folate deficiency and 
zidovudine induced anemia (39.1%), anemia of chronic disease (26.1%) & anemia 
secondary to hemolysis (8.7%). There were no cases of anemia secondary to bone 
marrow infiltration in patients with CD4 count > 200/μl.  
Among  patients with CD4 count less than 200/μl, 86% of patients had 
more than normal marrow iron staining whereas in patients with CD4 count >  200/μl, 
only 56% had high bone marrow iron stores. (p=0.002). This indicates that with 
increasing immunodeficiency anaemia of chronic disease becomes more common. 
In our study mean hemoglobin of patients on HAART (5.58 gm/dl) was 
found to be low comparing to people not on HAART (7.52 gm/dl). (P<0.001). This could 
be because patients on HAART would obviously have had more advanced disease. 
There was significant difference in the hemoglobin levels in patients on 
zidovudine (5.54gm/dl) and non-zidovudine regimens (6.98 gm/dl) (P=0.011). Twenty 
seven percent of patients on zidovudine had zidovudine induced anemia. Among patients 
with zidovudine induced anemia, 37.5% had normocytic, normochromic picture and 
others showed macrocytic changes. 
The mean mean corpuscular volume was significantly higher in patients 
on ART (91.9 fl) compared to patients not on ART (84.2 fl). (P=0.030) There was no 
relevant  difference in the mean MCV in patients on zidovudine (92.11fl) & those not on 
zidovudine (91.51fl). 
The mean hemoglobin was significantly higher in newly diagnosed 
patients (7.34 gm/dl) compared to patients who had been diagnosed earlier. This could 
signify an earlier stage of disease in newly diagnosed individuals.   
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8. SUMMARY 
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HIV positive patients have anemia  is increasing in frequency that is 
parallel to the increasing number of new cases seen world over. The World Health 
Organization (WHO) estimates that around 36.7 million peoples  in the world are 
infected with HIV. Approximately 95% of these cases as well as deaths from AIDS 
occur in the developing world. India has the 2nd  largest burden of HIV related 
pathology, after Sub-Saharan Africa. Of the subtypes of HIV virus, subtype C is 
responsible for more than 50% of HIV 1 infections causing rapidly growing 
epidemics in India.  
               HIV positive patients maximum incidence of anemia  will ranges from 10% 
in asymptomatic patients to 92% in individuals with full blown AIDS. In HIV positive 
patients anemia is a prognostic marker for  future disease progression or death, not 
dependent  of CD4 count and viral load. Though anemia directly does not contribute 
to mortality, it causes significant morbidity. Anemia impacts a range of dimensions of 
quality of life. The common causes of anemia in Humanimmunodeficiency  and non 
HIV patients are different & treatment will differ. It may require the modification of 
antiretroviral drugs and the drugs used for the treatment of opportunistic infections. 
Hence knowledge of the pathophysiological mechanisms and the prevalence of 
various causes of anemia will help us in treatment of anemia in HIV positive patients.  
Very few studies have studied the etiology of anemia in these patients 
in developing countries. The objective of our study was to study the etiology of 
anemia in HIV positive patients and to study the relationship between anemia and 
immunological status as indicated by the CD4 count. This was a descriptive cross 
sectional study conducted in Medical wards in MADRAS MEDICAL 
COLLEGE,CHENNAI. 
Sixty HIV positive patients with HIV and anemia (Grade I or greater of 
WHO/ACTG criteria) were analyzed. Mean age was 40.97 years. Seventy three 
percent of the subjects were male. Among the patients in the study, 76.6% had their 
diagnosis established within 1 year of this study and 23.3% had their diagnosis 
established greater than one year ago. CD4 count was lesser than 200/μl in 58% of 
patients. Sixty  percentage of the patients were on HAART. 16.7% grade one, 
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31.7% percent had grade two anemia, 18.3%% had grade three and 
38.3% had grade four anemia. Seventeen percent had MCV less than 76 fl and 13% 
had MCV greater than 96 fl. Sixty percent of patients with MCV less than 76 fl had 
iron deficiency anemia. Microcytosis cannot be taken as indicative of iron deficiency. 
Among the patients with macrocytosis 87.5% had B12/folate deficiency and 12.5% 
had zidovudine induced anemia. Fifteen pecent of the patients had positive direct 
antiglobulin (Coomb’s) test (DCT). However, only 3% had evidence of hemolysis. 
13% had low vitamin B12 levels. In our study only 50% percent of patients with low 
B12 levels had macrocytosis. Though 10% of patients in our study had absolute iron 
deficiency only 5% of patients had low serum ferritin levels. In peripheral smear 
examination, 78% of the patients had normocytic normochromic anemia. Eighty 
seven percent had normocellular and 13% were found to have hypocellular marrow.  
The largest number of patients had anemia of chronic disease in 
comparison to other etiologies. Fifty two percent had anemia of chronic disease, 15% 
had B12/folate deficiency, 10% had bone marrow infiltration, 10% had iron 
deficiency anemia, 10% had zidovudine induced anemia and 3% had anemia due to 
hemolysis.  
Among the patients who had bone marrow infiltration (n = 6), 33.3 % 
had tuberculosis and 66.6 % had lymphoma. All the patients with lymphoma had CD4 
count less than 200/μl. This underscores the significant  of bone marrow examination 
in the evaluation of anemia in these patients especially in patients with CD4 counts <  
200/μl.  
There was  significant difference in hemoglobin values among patients 
who had CD4 count <  200/μl and CD4 count greater than 200/μl. In patients with 
CD4 count >  200/μl, anemia of chronic disease was less common and other etiologies 
were comparable to HIV negative patients. 27% of patients on zidovudine had 
zidovudine induced anemia.  
The mean corpuscular volume was significantly higher in patients on 
ART compared to patients not on ART. There was no relevant  difference in the  
MCV in patients on zidovudine and those not on zidovudine..  
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The etiology of anemia is different in HIV positive patients, especially 
in patients with CD4 count less than 200/μl comparing to HIV negative patients. 
Evaluation of anemia should focus on establishing a specific etiology as the 
therapeutic options differ based on the etiology. 
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10. ANNEXURE 
 
  
PROFORMA 
Name      Ht/Wt  
Age  
Sex  
Occupation  
Address  
Marital status  
Duration since HIV diagnosis  
CD4 count  
Treatment details 
• HAART  
(1)ZDV/non ZDV containing regimen –  
Duration of treatment  
• Anti opportunistic treatment  
Co trimoxazole  
Dapsone  
Gancyclovir  
Total count 
Hemoglobin  
Reticulocyte proliferation index  
MCV  
Peripheral smear  
Dct 
Vitamin B12 levels 
Serum iron 
Serum ferritin 
If needed investigations : 
      Bone marrow Aspiration  
  Presence or absence of erythropoisis  
  Cellularity  
  Type of maturation  
  Iron stores  
  Reticulin in the bone marrow  
     Biopsy  
  Infiltration by lymphoma/fungus/granuloma  
   Stool routine  
  Microscopy  
  Occult blood  
 Sputum AFB 
 FNAC 
      LN biopsy  
Abdomen USG  
LFT  
Clinical features  
Presence/absence of PUO  
Predominant system involved  
Final diagnosis  
Presence of clinical AIDS defining illness 
 
 
  
LIST OF ABBREVIATIONS USED 
 
 
ACTG AIDS   Clinical Trial Group  
AIDS    Acquired immune deficiency syndrome  
ART    Anti retroviral therapy  
AZT    Zidovudine  
CCR5    C-C chemokine receptor type 5  
CD    Cluster of differentiation  
CDC    Centre for disease control  
CXRCR5   C-X-C chemokine receptor type 5 
DCT    Direct coobs test   
DNA    Deoxy ribo nucleic acid  
D4T    Stavudine  
EURO SIDA   European Swedish International Development Co-operation Agency  
ELISA   Enzyme linked immunosorbent assay  
FDA    Food and drug administration  
Fe    Iron 
G- CSF   Granulocyte colony stimulating factor  
HAART   Highly active anti retroviral therapy.  
HBV    Hepatitis B virus  
Hb   Hemoglobin    
HCV    Hepatitis C virus  
HIV    Human Immunodeficiency virus  
IL   Interleukin  
KS    Kaposi Sarcoma  
MCV    Mean corpuscular volume.  
MAI    Mycobacterium avium intracellulare  
MHC    Major Histocompatibility complex  
NACO   National AIDS control organization. VIII 
OI    Opportunistic infections  
NHL    Non hodgkins lymphoma  
NRTI    Nucleoside reverse transcriptase inhibitors.  
PCP    Pneumocystis jiroveci pneumonia  
WHO    World Health Organisation.  
3TC    Lamivudine  
ZDV    Zidovudine IX  
 

INFORMATION SHEET 
We are conducting a study on “A STUDY OF FACTORS 
ASSOCIATED WITH ANEMIA IN HIV INFECTED INDIVIDUALS IN 
A TERTIARY CARE HOSPITAL” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your specimen may 
bevaluable to us. 
The purpose of this study is to find the factors a associated with 
anemia in HIV patients in tertiary care hospital. In HIV patients admitted in 
medical ward, clinical history of patients are taken, then laboratory 
investigations will be done after their consent, blood collected for blood 
haemoglobin, ferritin, CBC, peripheral smear, serum ferritin and B12  level, 
DCT, Bone marrow aspiration and other necessary investigations are taken to 
find cause of anemia. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation resulting 
from the research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your decision 
will not result in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the 
end of the study period or during the study if anything is found abnormal which 
may aid in the management or treatment. 
 
Signature of Investigator           Signature of Participant 
Date : 
Place : 


PATIENT CONSENT FORM 
Study Detail : “A STUDY OF FACTORS ASSOCIATED WITH 
ANEMIA IN HIV INFECTED INDIVIDUALS IN A 
TERTIARY CARE HOSPITAL” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
Patient may check (☑) these boxes 
 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study. 
 
 ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study ❏ 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests. ❏ 
 
 
Signature/thumb impression 
Patient’s Name and Address:    Signature of Investigator 
Study Investigator’s Name: 
Dr. SENTHIL A   
  

 
 
 
 
 
 
MASTER CHART 
  
NAMES AGE SEX IP NO MARITAL STATUS HIV ELISA DRUGS DURATION OF DISEASES CD4  COUNTS ART Hb% MCV T C PLATELETS COUNT R P I % S.B12 P S DCT S.FERRITIN
SEKAR 28 MALE 83917 UNMARRIED POSITIVE NO < ONE MONTH > 200 N 11 90 >4000 > ONE LAKSH < 2.5 N NNA P > 24
MUTHAIYAN 40 MALE 84018 MARRIED POSITIVE YES EIGHT MONTHS < 200 Y 8.5 79 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
SRINIVASAN 45 MALE 108800 MARRIED POSITIVE YES SEVEN MONTHS < 200 Y 9.2 85 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
YUVARAJ 29 MALE 114469 UNMARRIED POSITIVE NO < ONE MONTH > 200 N 10 < 76 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
SANJEEV KUMAR 44 MALE 60460 MARRIED POSITIVE YES TEN MONTHS < 200 Y 9.3 94 < 4000 > ONE LAKSH < 2.5 N NNA P > 24
MUNUSAMY 52 MALE 117437 MARRIED POSITIVE YES SIX MONTHS < 200 Y 7.5 > 96 < 4000 < ONE LAKSH < 2.5 L Mg A N > 24
ARUNACHALAM 42 MALE 120070 MARRIED POSITIVE YES EIGHT MONTHS < 200 Y 8.1 < 76 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
RAGUPATHY 51 MALE 66124 MARRIED POSITIVE YES FIVE MONTHS < 200 Y 7.1 > 96 < 4000 > ONE LAKSH < 2.5 L Mg A N > 24
VENKATESAN 32 MALE 134575 MARRIED POSITIVE NO < ONE MONTH > 200 N 9.7 92 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
ABDUL SATHAR 52 MALE 91852 MARRIED POSITIVE YES ELEVEN MONTHS < 200 Y < 6.5 79 < 4000  > ONE LAKSH < 2.5 N NNA P > 24
SRINVASAN 35 MALE 19495 MARRIED POSITIVE YES < ONE MONTH > 200 N 9.2 82 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
SENTHIL KUMAR 36 MALE 24924 MARRIED POSITIVE YES FOUR MONTHS < 200 Y 9.3 85 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
SURESH 40 MALE 2408 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y 7.8 < 76 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
SUDHAKAR 30 MALE 3391 UNMARRIED POSITVE NO < ONE MONTH > 200 N 10 94 > 4000 > ONE LAKSH < 2.5 N MNA N > 24
MUNNA 48 MALE 10660 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y 8.5 > 96 < 4000 > ONE LAKSH < 2.5 L NNA P > 24
RAJENDRAN 50 MALE 13516 MARRIED POSITIVE YES NINE MONTHS < 200 Y 9.2 83 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
KANNIYAPPAN 42 MALE 17128  MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y < 6.5 79 < 4000 < ONE LAKSH < 2.5 N NNA N > 24
VENUGOPAL 60 MALE 21775 MARRIED POSITIVE YES SIX MONTHS < 200 Y < 6.5 > 96 < 4000 < ONE LAKSH > 2.5 L Mg A N > 24
SHANKAR 42 MALE 40940 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y 8.7 76 < 4000 > ONE LAKSH < 2.5 N MNA N > 24
SYED MEER SHEIK 44 MALE 62611 MARRIED POSITIVE YES < ONE MONTH > 200 Y 7.5 < 76 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
ANANDHAN 42 MALE 62648 MARRIED POSITIVE YES SEVEN MONTHS < 200 Y 8.8 78 < 4000 > ONE LAKSH < 2.5 N MNA N > 24
SARAVANAN 27 MALE 65572 UNMARRIED POSITIVE NO < ONE MONTH > 200 N 11 94 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
RAMESH KUMAR 48 MALE 68095 MARRIED POSITIVE YES THREE MONTHS > 200 Y < 6.5 88 < 4000 > ONE LAKSH < 2.5 N MNA N > 24
PANNER SELVAM 48 MALE 73976 MARRIED POSITIVE YES < ONE MONTH < 200 Y 6.9 > 96 < 4000 > ONE LAKSH < 2.5 L Mg A N > 24
DEVAN 58 MALE 76903 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y < 6.5 79 < 4000 < ONE LAKSH < 2.5 N NNA N > 24
PANDIYAN 45 MALE 90676 MARRIED POSITIVE YES NINE MONTHS < 200 Y < 6.5 82 < 4000 > ONE LAKSH < 2.5 N MNA N > 24
SHANTHI 40 FEMALE 343108 MARRIED POSITIVE YES TEN MONTHS < 200 N 8.6 89 > 4000 > ONE LAKSH < 2.5 N NNA P > 24
SASIKALA 36 FEMALE 76354 MARRIED POSITIVE YES TWO MONTHS > 200 N 9.6 91 > 4000 > ONE LAKSH < 2.5 N MNA N > 24
CHELLAMMAL 50 FEMALE 90197 MARRIED POSITIVE YES < ONE MONTH < 200 Y < 6.5 90 < 4000 > ONE LAKSH < 2.5 N MNA N > 24
SASIKALA 43 FEMALE 95719 MARRIED POSITIVE YES EIGHT MONTHS > 200 N 8 < 76 > 4000 > ONE LAKSH < 2.5 N NNA P > 24
DEVI 60 FEMALE 69934 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y < 6.5 77 < 4000 < ONE LAKSH > 2.5 N NNA N < 24
THILAGAVATHY 32 FEMALE 94395 MARRIED POSITIVE YES FIVE MONTHS > 200 N 11 90 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
MORJINA 30 FEMALE 72109 UNMARRIED POSITIVE NO < ONE MONTH > 200 N 9 95 > 4000 > ONE LAKSH < 2.5 L Mg A N > 24
CHENNAUER BARATI 45 FEMALE 88897 MARRIED POSITIVE YES SIX MONTHS < 200 N 7.4 < 76 > 4000 > ONE LAKSH < 2.5 N MNA N > 24
MEENA 30 FEMALE 23927 MARRIED POSITIVE YES < ONE MONTH < 200 Y 10 94 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
RANJITHAM 45 FEMALE 29570 MARRIED POSITIVE NO < ONE MONTH > 200 N 7.8 85 > 4000 > ONE LAKSH < 2.5 N MNA N > 24
KANTHAKUMARI 37 FEMALE 33304 MARRIED POSITIVE YES THREE MONTHS < 200 N 8.7 91 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
SHANTHI 35 FEMALE 60784 MARRIED POSITIVE YES > TWELVE MONTHS > 200 N 9.2 95 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
GOMATHI 26 FEMALE 104849 UNMARRIED POSITIVE NO < ONE MONTH > 200 N 10 89 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
JAYANTHI 22 FEMALE 100224 UNMARRIED POSITIVE NO < ONE MONTH > 200 N 9.1 86 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
RANI 45 FEMALE 105634 MARRIED POSITIVE YES ELEVEN MONTHS < 200 Y 7.3 > 96 < 4000 > ONE LAKSH < 2.5 L Mg A N > 24
GOWRI 45 FEMALE 105805 MARRIED POSITIVE YES > TWELVE MONTHS > 200 N < 6.5 78 > 4000 > ONE LAKSH < 2.5 N NNA P > 24
PANDIMEENA 37 FEMALE 72816 MARRIED POSITIVE YES SEVEN MONTHS < 200 Y 9.2 < 76 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
RAJATHI 33 FEMALE 76884 MARRIED POSITIVE YES NINE MONTHS < 200 Y 8.9 87 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
DEVAN 47 MALE 61953 MARRIED POSITIVE NO < ONE MONTH > 200 N 6.9 80 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
SRINIVASALU 47 MALE 61953 MARRIED POSITIVE NO < ONE MONTH > 200 N < 6.5 76 > 4000 > ONE LAKSH < 2.5 N MNA P > 24
RAMESH 43 MALE 87150 MARRIED POSITIVE YES EIGHT MONTHS < 200 Y < 6.5 79 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
JOSEPH 44 MALE 89783 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y < 6.5 > 96 < 4000 > ONE LAKSH < 2.5 L Mg A N > 24
VIJAYARAGHAVAN 46 MALE 126315 MARRIED POSITIVE YES SEVEN MONTHS > 200 N < 6.5 80 > 4000 > ONE LAKSH < 2.5 N MNA N > 24
EZHILKUMAR 40 MALE 12535 MARRIED POSITIVE YES EIGHT MONTHS < 200 Y 6.9 < 76 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
RAVI 50 MALE 23699 MARRIED POSITIVE NO < ONE MONTH > 200 N < 6.5 79 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
SRINIVASAN 45 MALE 16890 MARRIED POSITIVE NO < ONE MONTH > 200 N < 6.5 78 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
MURUGAPANDIYAN 53 MALE 19771 MARRIED POSITIVE YES ELEVEN MONTHS < 200 Y < 6.5 82 < 4000 < ONE LAKSH < 2.5 N NNA N > 24
SHEIK MALIK 27 MALE 22930 MARRIED POSITIVE NO < ONE MONTH > 200 N 9.5 80 > 4000 > ONE LAKSH < 2.5 N NNA N > 24
UDAYA KUMAR 42 MALE 28065 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y < 6.5 < 76 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
KARTHIKEYAN 32 MALE 91530 MARRIED POSITIVE NO < ONE MONTH > 200 N 9.4 94 > 4000 > ONE LAKSH < 2.5 N NNA P > 24
ANANDHAN 40 MALE 85234 MARRIED POSITIVE YES SIX MONTHS < 200 Y < 6.5 92 < 4000 > ONE LAKSH < 2.5 N NNA N > 24
SELVARAJ 40 MALE 85866 MARRIED POSITIVE YES TEN MONTHS < 200 N 7.8 84 < 4000 > ONE LAKSH < 2.5 N NNA N < 24
NAGARAJ 35 MALE 83236 MARRIED POSITIVE YES FIVE MONTHS > 200 N < 6.5 > 96 > 4000 > ONE LAKSH < 2.5 L Mg A N > 24
JAGAN 42 MALE 95394 MARRIED POSITIVE YES > TWELVE MONTHS < 200 Y < 6.5 < 76 < 4000 < ONE LAKSH < 2.5 N NNA N > 24
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ART- antiretroviral therapy, Hb- hemoglobin, MCV- mean corpuscular volume, TC- total count, RPI- Reticulocyte proliferation index, PS - Peripheral smear, DCT - Direct coomb's test
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